COVID-19 Impact on Kazakhstan University Student Fear,Mental Health,and Substance Use

International Journal of Mental Health and Addiction -     

Fatty acid profiles,antioxidant status,and growth of preterm infants fed diets without or with long-chain polyunsaturated fatty acids

Summary. Long-chain polyunsaturated fatty acids (LCP) are considered conditionally essential nutrients for the infant born prematurely, and attempts are being made to match fatty acid profiles of formula and breast fed infants. In this double-blind, randomized study we investigated the effects of a formula enriched with both n-6 and n-3 LCP on plasma fatty acid profiles, antioxidant status and growth of premature infants. 29 infants received either a formula devoid of LCP or a LCP supplemented formula (0.5 g/100 g fat linoleic acid metabolites, 0.8 g/100 g fat -linolenic acid metabolites). 17 breast fed infants served as a control group. At study entry as well as two and four weeks later, plasma and urine samples were collected, growth data obtained and food tolerance was documented. At the end of the four week study period, plasma docosahexaenoic acid (DHA) levels of supplemented infants were significantly higher than those of unsupplemented infants and similar to those of infants fed human milk. Plasma n-6 LCP concentrations including arachidonic acid (AA) were similar between groups. The plasma -tocopherol levels of breast fed and supplemented infants were similar and tended to be lower than in infants fed the formula devoid of LCP. Urinary malondialdehyde (MDA) excretion of formula fed infants was significantly higher compared to infants fed human milk, but did not differ between the two formula groups. Parameters of growth and milk tolerance did not differ between groups. Our results demonstrate that plasma LCP levels similar to those of breast fed infants can be achieved with the LCP supplemented formula used in this trial, without evidence of adverse effects of the LCP enrichment.AA arachidonic acid - ALA -linolenic acid - DGLA dihomo--linolenic acid - DHA docosahexaenoic acid - EPA eicosapentaenoic acid - F formula devoid of LCP - GLA -linolenic acid - HM human milk - LA linoleic acid - LCP long-chain polyunsaturated fatty acids - LCP-F formula enriched with LCP - MDA malondialdehyde - PC phosphatidylcholine - PCA postconceptional age - PE phosphatidylethanolamine - PUFA polyunsaturated fatty acid     

Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion

Plasmodium vivax is the major cause of malaria outside sub-Saharan Africa and inflicts debilitating morbidity and consequent economic impacts in developing countries. In order to produce a P. vivax vaccine for global use, we have previously reported the development of a novel chimeric recombinant protein, VMP001, based on the circumsporozoite protein (CSP) of P. vivax. Very few adjuvant formulations are currently available for human use. Our interest is to evaluate second-generation vaccine formulations to identify novel combinations of adjuvants capable of inducing strong, long-lasting immune responses. In this study rhesus monkeys were immunized intramuscularly three times with VMP001 in combination with a stable emulsion (SE) or a synthetic Toll-like receptor 4 (TLR4) agonist (glucopyranosyl lipid A [GLA]) in SE (GLA-SE). Sera and peripheral blood mononuclear cells (PBMCs) were tested for the presence of antigen-specific humoral and cellular responses, respectively. All groups of monkeys generated high titers of anti-P. vivax IgG antibodies, as detected by enzyme-linked immunosorbent assays (ELISAs) and immunofluorescence assays. In addition, all groups generated a cellular immune response characterized by antigen-specific CD4(+) T cells secreting predominantly interleukin-2 (IL-2) and lesser amounts of tumor necrosis factor (TNF). We conclude that the combination of VMP001 and GLA-SE is safe and immunogenic in monkeys and may serve as a potential second-generation vaccine candidate against P. vivax malaria.     

Plasma amino acid level in premature and newborn infants after infusion of 2 commercial pediatric amino acid solutions]

13 preterms and 10 term-babies were fed with two commercially available amino acid solutions (mother milk-adapted and requirement-adapted) under the same test conditions. Method and results were compared and discussed. None of the solutions showed amino acid imbalances 4 hours after discontinuation of continuous infusion over 20 hours. This applies also to glutamic and aspartic acid which were not contained in the mother milk-adapted solution. Threonine and methionine showed more favorable levels after the infusion of the mother milk-adapted solution It was pointed out that additional monitoring of levels is mandatory in the course of continuous i.v. amino acid supplies.     

Disturbed absorptive function of small intestines in patients with chronic obstructive pulmonary disease

The study included 93 patients (mean age 56.8+/-7.2) with COPD; 22 presented with grade 1 COPD, 36 and 35 with grade II and 111 COPD respectively. The latter group displayed reduced absorption of fats, proteins, and carbohydrates in the small intestine, the degree of dysfunction increasing with the severity of the disease, degenerative/dystrophic changes in intestinal mucosa, and deterioration of its regenerative potential. The data obtained are interpreted in the context of the relationship between the functional/structural properties of intestinal mucosa and clinical manifestations. The body mass deficit in COPD patients was shown to positively correlate with the reduction of absorption of fats (r=0.55), proteins (r=0. 71), and carbohydrates (r=0.48) in the small intestine.     

Characterization of a MH2 mutant lacking the v-myc oncogene

We have previously reported that a virus, MH2-PA200, lacking the ability to transform quail embryo cells, could be isolated from wild type (wt) MH2 stocks passaged on chicken neuroretina cells. We report here the molecular cloning and extensive characterization of this MH2-PA200 provirus. Molecularly cloned MH2-PA200 DNA was found to stimulate the growth of neuroretina cells by transfection assays and our results indicate that this recombinant virus was derived from the RAV-1 helper virus, in which v-mil and a small part of v-myc of MH2 were acquired at the expense of helper (delta gag-pol-delta env) sequences. In order to assess the precise boundary between the myc and env genes we determined the nucleotide sequence of the junction fragment and showed that 11 of 13 nucleotides of the env gene were identical to the myc sequence at the recombination point. The nucleotide sequence of the myc-env junction fragment of another similar and independently generated MH2 mutant showed similarly 9 nucleotides of homology between the env and myc sequences at the recombination point that took place at another site, suggesting that a homologous recombination occurred between MH2 and RAV-1 viruses to generate MH2-PA200 and similar mutants.     

Cooperative effect of v-myc and v-erbA in the chick embryo.

We show that a construct designated as MAHEVA, which encodes oncogenes v-myc from MH2 virus and v-erbA from AEV under the control of the LTR of MH2, induces rapidly growing heart rhabdomyosarcomas, when it is injected in E3 but not E5 chick embryos. A similar pathology has previously been observed with MC29, within the same limited time frame. The tumors, which expressed P61-63myc, P75gag-erbA and Pr76gag proteins were detectable from E14 onwards. Compared with MC29, MAHEVA induced a secondary anomaly, not detectable prior to E17. This is the appearance of cartilage nodules within the heart rhabdomyosarcomas. The constant location of these nodules inside the rhabdomyosarcomas and their delayed appearance suggests that the chondrocytes originate from myoblasts prevented from differentiating by the expression of the v-myc product. This interpretation is supported by the appearance of chondrocytes in E3 heart muscle cells infected in vitro with MAHEVA.